Eisai Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$562.3M
Doctors Paid
69,858
Transactions
492,818
2024 Total
$30.5M
Payment Breakdown by Category
Research$475.6M (84.6%)
Consulting$59.7M (10.6%)
Food & Beverage$6.8M (1.2%)
Travel$3.1M (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $475.6M | 160,676 | 84.6% |
| Consulting Fee | $59.7M | 5,926 | 10.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12.4M | 7,807 | 2.2% |
| Food and Beverage | $6.8M | 300,473 | 1.2% |
| Travel and Lodging | $3.1M | 10,857 | 0.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2.8M | 1,800 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $1.1M | 484 | 0.2% |
| Grant | $713,775 | 107 | 0.1% |
| Education | $83,645 | 4,688 | 0.0% |
Payments by Type
Research
$475.6M
160,676 transactions
General
$86.7M
332,142 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | $151.6M | 0 | 4,849 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors | $39.2M | 0 | 48,385 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder | $33.1M | 0 | 12,303 |
| A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | $30.9M | 0 | 17,255 |
| AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | $22.7M | 0 | 1,458 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | $22.7M | 0 | 11,162 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | $20.2M | 0 | 7,915 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease | $17.3M | 0 | 9,054 |
| A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) | $14.5M | 0 | 11 |
| A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease | $13.4M | 0 | 5,399 |
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma | $10.3M | 0 | 8,833 |
| A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder | $6.7M | 0 | 5,338 |
| An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) | $6.6M | 0 | 4,420 |
| A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid | $6.2M | 0 | 740 |
| A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma | $5.2M | 0 | 3,434 |
| A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) | $4.2M | 0 | 5,413 |
| An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects with Hepatocellular Carcinoma | $3.2M | 0 | 286 |
| A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | $3.1M | 0 | 152 |
| A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile | $3.1M | 0 | 430 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer | $2.9M | 0 | 338 |
| A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | $2.5M | 0 | 33 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease | $2.4M | 0 | 1,239 |
| A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | $2.0M | 0 | 1,069 |
| A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies | $2.0M | 0 | 1,416 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Moderate to Severe Obstructive Sleep Apnea and Adult and Elderly Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | $2.0M | 0 | 103 |
| A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years | $1.8M | 0 | 169 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia | $1.8M | 0 | 396 |
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome | $1.7M | 0 | 919 |
| An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors | $1.5M | 0 | 366 |
| A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy | $1.4M | 0 | 205 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Douglas Nordli, Md, MD | Neurology | Chicago, IL | $644,357 | $0 |
| Jesus Pina-Garza, Md, MD | Neurology | Nashville, TN | $501,385 | $0 |
| Ghassan Abou-Alfa, Md, MD | Medical Oncology | New York, NY | $460,992 | $0 |
| Keith Ridel, Md, MD | Neurology with Special Qualifications in Child Neurology | Indianapolis, IN | $422,983 | $0 |
| Matthew Holtzman, M.d, M.D | Clinical Neurophysiology | Wayne, MI | $401,209 | $0 |
| Selim Benbadis, Md, MD | Neurology | Tampa, FL | $395,865 | $0 |
| Daniel Weintraub, Md, MD | Psychiatry | Philadelphia, PA | $370,650 | $0 |
| Brian Moseley, Md, MD | Neurology | Cincinnati, OH | $343,475 | $0 |
| Dr. James Wheless, Md, MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $339,383 | $0 |
| Mahdi Taha, D.o, D.O | Medical Oncology | Deerfield Beach, FL | $319,205 | $0 |
| Atiya Khan, M.d, M.D | Neurology | Fort Wayne, IN | $295,940 | $0 |
| Imad Najm, Md, MD | Neurology | Cleveland, OH | $295,358 | $0 |
| Arnab Basu, Md, MD | Hematology & Oncology | Jacksonville, FL | $281,336 | $0 |
| Dr. Robert Wechsler, Md, Phd, Faan, MD, PHD, FAAN | Clinical Neurophysiology | Boise, ID | $272,686 | $0 |
| Pierre Gholam, Md, MD | Gastroenterology | Cleveland, OH | $271,335 | $0 |
| Dr. Amina Ahmed, Md, MD | Gynecologic Oncology | Chicago, IL | $251,923 | $0 |
| Michael Morse, M.d, M.D | Hematology & Oncology | Durham, NC | $229,995 | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $224,384 | $0 |
| Dr. John Hemphill, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Savannah, GA | $216,279 | $0 |
| Amit Verma, Md, MD | Neurology | Houston, TX | $211,741 | $0 |
| Dr. Mark Lupo, Md, MD | Endocrinology, Diabetes & Metabolism | Sarasota, FL | $206,738 | $0 |
| Julio Cantero, Md, MD | Sleep Medicine | Sarasota, FL | $181,079 | $0 |
| Trevor Resnick, Md, MD | Neurology with Special Qualifications in Child Neurology | Miami, FL | $175,167 | $0 |
| Jeffrey Cummings, Md, MD | Neurology | Los Angeles, CA | $172,731 | $0 |
| Dr. Heidi Godoy, Do, DO | Gynecologic Oncology | Albany, NY | $168,168 | $0 |
Ad
Top Products
- Lenvima $86.7M
- Leqembi $85.9M
Associated Products (13)
Payment Categories
- Food & Beverage $6.8M
- Consulting $59.7M
- Travel & Lodging $3.1M
- Research $475.6M
About Eisai Inc.
Eisai Inc. has made $562.3M in payments to 69,858 healthcare providers, recorded across 492,818 transactions in the CMS Open Payments database. In 2024, the company paid $30.5M. The top product by payment volume is Lenvima ($86.7M).
Payments were distributed across 292 medical specialties. The top specialty by payment amount is Neurology ($10.6M to 5,122 doctors).
Payment categories include: Food & Beverage ($6.8M), Consulting ($59.7M), Research ($475.6M), Travel & Lodging ($3.1M).
Eisai Inc. is associated with 13 products in the CMS Open Payments database, including Lenvima, Leqembi, and Belviq.